Serum Levels of the Adipokine Chemerin in Relation to Renal Function
- Dörte Pfau, MS1,
- Anette Bachmann, MD1,
- Ulrike Lössner, BS1,
- Jürgen Kratzsch, PHD2,
- Matthias Blüher, MD1,
- Michael Stumvoll, MD1 and
- Mathias Fasshauer, MD1
- 1Department of Internal Medicine III, University of Leipzig, Leipzig, Germany;
- 2Institute of Laboratory Medicine, University of Leipzig, Leipzig, Germany.
- Corresponding author: Mathias Fasshauer, mathias.fasshauer{at}medizin.uni-leipzig.de.
-
D.P. and A.B. contributed equally to this study.
Abstract
OBJECTIVE To investigate serum levels of the adipokine chemerin in patients on chronic hemodialysis (CD) as compared with control patients with a glomerular filtration rate (GFR) >50 ml/min.
RESEARCH DESIGN AND METHODS Chemerin was quantified by ELISA in control patients (n = 60) and CD patients (n = 60) and correlated with clinical and biochemical measures of renal function, glucose, and lipid metabolism, as well as inflammation, in both groups.
RESULTS Median serum chemerin levels were more than twofold higher in CD patients (542.2 μg/l) compared with subjects with a GFR >50 ml/min (254.3 μg/l) (P < 0.001). Furthermore, GFR, as assessed by the original Modification of Diet in Renal Disease formula, independently predicted circulating chemerin concentrations in multiple regression analyses in both control patients (P < 0.05) and CD patients (P < 0.01).
CONCLUSIONS We demonstrate that markers of renal function are independently related to circulating chemerin levels.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Received July 23, 2009.
- Accepted October 7, 2009.
- © 2010 by the American Diabetes Association.
